EDAP TMS - Focal One HIFU
by EDAP TMS
EDAP TMS - Focal One HIFU
Follow Us
DESCRIPTION
The Focal One HIFU device is the first medical apparatus designed specifically for the Focal treatment of Prostate Cancer.The Focal One HIFU has been developed with the last evolutions of HIFU technology and imaging fusion software to answer all the specificities of PCa Focal treatment.
Focal treatment strategy for Prostate Cancer (PCa) is playing a growing role in today's surgical practice. By combining the latest imaging and treatment technologies, Focal One brings the answer to current requirements for ideal focal therapy: accurate and MR-fused imaging, non-invasive approach, precise and efficient therapeutic HIFU energy and end-of-treatment validation imaging with Contrast-Enhanced Ultrasound.
FORUMSView All (2)
0Replies10 years ago | Focal One Video Live treatment of prostate cancer with Focal One device. Focal treatment step by step. Dr S Crouzet and A Gelet at Edouard Herriot Hospital in Lyon, France. Reply |
0Replies10 years ago | Focal One - Robot-Assisted Prostate Tumorectomy. Reply |
SERVICE COMPANIESView All Ultrasound Systems Companies
VIDEOS
Focal One Video...
Focal One - Robot-Assisted Pro...
FEATURES
- MRI Import and Fusion with real-time ultrasound imaging
- Precise contour definition of target areas
- Non-invasive ultimate HIFU technology
- Precise robotic movement
- Unique Dynamic Focusing technology
- Real-time tracking and adjustment of energy delivered
- Confirmation and possible completion of untreated area
- Quality of Life preservation
- All treatments remain salvage options
- A precise cancer localization
- A precise treatment
- An immediate treatment validation
- Precise treatment of the diagnosed tumor
- Preservation of patient's quality of life
- Possibility to perform any other treatment if needed
| Cart Based | 1 |
| Portable | 1 |
NEWSView All
Health Canada Approves Focal One HIFU Device for Prostate...
EDAP TMS has announced that its Focal One HIFU device received approval from Health Canada in January 2015. This approval authorizes the company to market the Focal One device for the treatment of prostate cancer throughout Canada.